The Darius Gant Show Darius Gant

Artificial Intelligence (AI) has revolutionized how businesses operate, and supply chain management and insurance are no exceptions. With the ability to analyze vast amounts of data and identify patterns, AI has the potential to transform supply chain operations and insurance claims management, making them more efficient, cost-effective, and responsive to customer demands. In this thought leadership article, we explore the power of AI in supply chain management and insurance.
 
In this episode, we sit with Stan Smith CEO of Gradient AI. Stan has founded six companies and has been working with machine learning and AI since the late 1990s. Stan shares his experiences working with AI and machine learning, starting with his first startup that focused on supply chain management. He discusses how his company used machine learning to predict which suppliers were likely to have issues and how this helped his clients save millions of dollars. Stan also talks about the pain point he saw in the insurance market and how Gradient AI is assisting businesses to leverage AI to solve complex problems and improve their operations. In this episode, Stan also talks about the importance of equity in startups, the challenges of building AI solutions in the insurance industry, and the measures Gradient AI took to ensure client data was secure.
 
If your company is looking to scale its AI initiatives, head over to Tesoro AI (www.tesoroai.com). We are experts in AI strategy, staff augmentation, and AI product development. 
 
Founder Bio: 
Stan Smith is the  Founder and CEO of Gradient AI. Stan founded Gradient AI, first as a unique practice within Milliman to focus on the risk management and insurance industry’s most challenging business problems. He acquired the business from Milliman in 2018, founding Gradient AI as a rapidly growing independent SaaS organization. With nearly 30 years of experience growing AI and technology organizations, Stan’s leadership ensures that Gradient AI is applying the latest Artificial Intelligence and Machine Learning technologies to the insurance industry, resulting in proven financial performance for its stellar list of customers and better treatment and outcomes for individuals. Stan has held founding or executive-level roles for multiple startup companies, including Vice President at MatrixOne, Executive Vice President and General Manager at Agile Software, and CEO and Founder at OpenRatings.Stan also led the development of patented technologies including: technology that predicts bankruptcies for small, privately held suppliers; a global database to improve supplier performance for more than 80 million companies; and, technology that combines assessments with performance data to identify opportunities for reducing inefficiencies through lean initiatives.




Time Stamps: 
02:17 Stan Smith's background and experience in the startup world
06:15 Paint point that led to the idea for Gradient AI
09:04 Importance of identifying high-risk claims early 
12:18 Ability of Gradient AI's models to accurately predict the cost of a claim
14:32 The complementary nature of AI and human adjusters in claims processing
17:07 Engaging with clients in underwriting operations
19:52 Integration of Gradient AI solutions into commercial systems
23:40 Challenges of building AI solutions in the insurance industry
25:11 Importance of having a team with both AI and insurance expertise
27:14 The importance of culture and team in attracting talent
29:36 Incentives that Gradient AI offers to attract the right talent
32:51 Educating insurance companies about AI and the impact of the pandemic
37:29 Turning interest in AI into investible business problems
40:14 Fundraising journey and partnerships with insurance-focused venture capitalists
41:57 Selecting investors based on industry and AI experience
43:44 Whats coming up new for Gradient AI
44:10 How to get in contact with the Gradient AI team
 
Resourc

In this episode, we sit with Dr. Karim Galil, the founder and CEO of Mendel.AI, an artificial intelligence-powered platform that extracts insights from medical records to improve patient outcomes. Dr. Galil shares his journey from practicing medicine to becoming a tech entrepreneur and the role that AI can play in making healthcare more data-driven. He discusses the challenges of subjective medical practices and the potential for AI to learn from every patient's journey.
 
Dr. Galil explains that symbolic AI is more focused on teaching machines fundamentals of logic, rules, and concepts, while machine learning is more focused on learning from patterns. He gives an example of the opioid crisis, where a machine learning model would learn that opioids are great because humans are prescribing them, while a symbolic system would understand what opioids are and what the best options are. In the process of building AI in healthcare, Mendel.AI has used both symbolic AI and machine learning. Dr. Galil also discusses the challenges of talent acquisition in the AI industry and how the economy can impact AI talent availability. He emphasizes the importance of hiring talent with grit, curiosity, and coachability and the benefits of hiring mid-level to junior talent to assist the genius.
 
Mendel.AI is a healthcare platform that uses symbolic AI and machine learning to provide personalized treatment plans for patients. The platform reads every medical record and encounter between patients and healthcare systems to help physicians make more objective decisions. Mendel.AI works with big pharmaceuticals, payers, and data companies to help them read their data and glean insights to make better decisions. The platform can help pharmaceutical companies understand which patients respond better to what drug and in what occasions, and payers can decide whether to cover a certain medication or not. Mendel.AI uses domain experts to learn from, rather than just data and can help pharmaceutical companies discontinue drugs that are not effective and optimize their drug offerings.
 
If your company is looking to scale its AI initiatives, head over to Tesoro AI (www.tesoroai.com). We are experts in AI strategy, staff augmentation, and AI product development. 
 
Founder Bio: 
Dr. Karim Galil, MD, is the CEO and Co-founder of Mendel.AI. Mendel's mission is to learn from every patient by structuring and de-identifying patient data at a machine scale and human fidelity to power clinical and research use cases. Dr. Galil’s experience as a physician demonstrated that medicine does not advance at the same rate as technology. With Mendel, he aims to bridge this gap, facilitate clinical research at scale, and make medicine objective. Dr. Galil’s expertise in AI, medical informatics, and digital health makes him a sought-after presence at global conferences.
 
Time Stamps: 
01:49 Introduction of Dr. Karim Galil and his background in medicine 
06:59 The potential for AI to learn from every patient's journey
10:41 The challenges of working with unstructured medical data 
12:19 The importance of explainable AI in healthcare 
15:20 Using real-world data to identify drug effectiveness in specific patient profiles
18:02 The difference between machine learning and symbolic AI 
21:09 Difference in talent and approach needed for symbolic AI vs machine learning
23:02 The process of building concepts for symbolic AI
25:53 Challenges of talent acquisition in the AI industry
27:49 The impact of the economy on AI talent availability
31:49 The importance of hiring talent with grit, curiosity, and coachability
35:18 Building a competitive advantage and a mode in AI startups
38:53 Challenges of finding the right investors for AI startups 
41:51 The myth of VCs being a value add and the importance of cash and brand
43:01 Who is the end user and how do they engage with the product
45:49 How to get in contact with the Mendel team
 
Reso

Today we sit with Michael D. Abramoff, a neuroscientist and the founder of Digital Diagnostics, a company that leverages artificial intelligence (AI) to provide autonomous medical diagnosis. In this interview, Michael shares his background and how he got into AI, as well as his vision for the future of medical diagnosis. He discusses how he uses AI to make medical diagnoses, the challenges he faces, and the potential for AI to revolutionize healthcare. He also talks about his involvement in other AI-related projects and his thoughts on the ethical implications of AI in healthcare. In addition, Michael delves into the safety concerns surrounding AI, particularly with language learning models (LLMs), and the importance of ensuring that AI is safe and free of bias.
 
Michael’s vision for AI in healthcare goes beyond mere assistance or augmentation of human decision-making. He believes that AI can make diagnoses and treatment decisions autonomously, without the need for human intervention. However, the promise of autonomous AI must be balanced with the potential pitfalls. As he pointed out, AI that learns from biased or fallible humans can produce models that are worse off. In healthcare, this could lead to harm to patients if doctors blindly follow AI recommendations.
 
Digital Diagnostics is a company that uses AI to diagnose diabetic retinopathy and increase healthcare access for underserved patients. The AI is trained to detect specific lesions using clinical knowledge and chunk by chunk learning to avoid bias. Healthcare providers can approve or disapprove the AI's recommendations, and the company aims to supplement rather than displace professionals.
 
If your company is looking to scale its AI initiatives, head over to Tesoro AI (www.tesoroai.com). We are experts in AI strategy, staff augmentation, and AI product development.


Founder Bio:
Michael D. Abramoff, MD, PhD, is a fellowship-trained retina specialist, computer scientist, and entrepreneur. He is Founder and Executive Chairman of Digital Diagnostics, the first company ever to receive FDA clearance for an autonomous AI diagnostic system. To transform the quality, accessibility, and affordability of global healthcare through the automation of medical diagnosis and treatment. In primary care, it can instantaneously diagnose diabetic retinopathy and diabetic macular edema at the point of care. Dr. Abramoff developed an ethical foundation for autonomous AI that was used during the design and validation, and regulatory and payment pathways for autonomous AI. As the author of over 350 peer-reviewed publications in this field, he has been cited over 42,000 times, and is the inventor of 20 issued patents and many patent applications. Dr. Abramoff has mentored dozens of engineering graduate students, ophthalmology residents, and retina fellows. His passion is to use AI to improve the affordability, accessibility, and quality of care.
 
Time Stamps:
02:10 Michael's background as a neuroscientist and his interest in AI
05:37 Safety concerns surrounding AI, particularly with LLMs
07:08 The challenges of implementing AI in healthcare
09:07 The importance of AI supporting decision making rather than making decisions
11:02 The potential for AI to revolutionize healthcare
15:25 The importance of ensuring access to healthcare for all
18:40 The pain points behind creating Digital Diagnostics
21:49 Creating an ethical framework for regulation and reimbursement of AI
24:02 Potential for AI to outperform human experts in diagnosing medical conditions
26:00 Importance of clinical outcomes: acquiring data for AI and ensuring inclusivity
29:26 The impact of pigmentation on AI training data
31:37 Talent shortage in AI: transition from rule-based systems to machine learning
33:00 Understanding the fundamentals of AI despite increased efficiency
35:10 The need to prove the worth of AI in healthcare through clinical outcomes
37:24 How to get in contact with t

In this episode, we sit with Pankit Desai, a seasoned corporate leader with nearly three decades of experience in the tech industry. Pankit shares his insights into the ever-evolving world of technology and its profound impact on businesses and society. He also takes us on a journey through the waves of technological advancements he has witnessed throughout his career, from crowdsourcing to digital transformation. We explore the advantages these waves have brought, including labor arbitrage, price advantage, and time-to-market advantage, allowing companies to stay competitive in the ever-changing market landscape and we discover how technology has become an integral part of our daily lives, driven by the internet and the proliferation of mobile devices. 
 
The conversation then turns to the integration of artificial intelligence (AI) into businesses and organizations. Pankit highlights the prerequisites for AI success: data, compute capacity, and connectivity. They explore how these prerequisites have made AI more accessible, paving the way for its positive impact on various aspects of life. 
 
With a focus on security, Pankit shares his expertise in applying AI to tackle the challenges of a rapidly evolving threat landscape. He emphasizes the limitations of siloed security solutions and reveals how AI can provide real-time threat identification and response without additional manpower. He then recounts his own journey of founding Secure Tech eight years ago, where he leveraged AI to address the critical cybersecurity problem.
 
If your company is looking to scale its AI initiatives, head over to Tesoro AI (www.tesoroai.com). We are experts in AI strategy, staff augmentation, and AI product development. 
 
Founder Bio: 
Pankit Desai is an Indian entrepreneur and the co-founder and CEO of Sequretek, a cybersecurity, cloud security products, and services company. He co-founded Sequretek in 2013, along with Anand Naik, and has been instrumental in growing the company into a leading provider of cybersecurity and cloud security solutions. Before starting Sequretek, Pankit held various technology leadership and management roles in the IT industry across companies such as across companies such as NTT Data, Intelligroup, and Wipro Technologies. He holds a degree in computer engineering and has a strong background in technology and entrepreneurship.  At Sequretek, he is proud of the growth that this team has been able to achieve within a short duration. With product offerings that have found resonance with over 120 customers across industry segments, it has been able to grow at phenomenal growth rates and has ambitions to create India’s first truly global security product and solutions company. Under Pankit's leadership, Sequretek has won several awards and recognition for its innovative solutions and commitment to the cybersecurity industry.
 
Time Stamps: 
01:56 Pankit’s background on AI and the impact of technology on everyday life
06:07 Impact of AI on businesses and organizations
09:35 Exploring the power of AI in cybersecurity
12:39 Possibility of AI-driven security solutions for data consumption and threat response
14:23 Zero-day threats and data acquisition strategies
19:27 AI product differentiation and competitive advantage
21:32 Benefits of AI for security challenges
25:30 Building trust and acquiring customers in the cybersecurity space
27:59 Closing deals and raising capital
30:05 Leveraging AI and security to run a capital efficient business
32:46 Using offshore talent for capital efficiency in the product build lifecycle 
34:44 Leveraging talent in India for product engineering success
37:18 Strategies for building a secure and successful business in 2023
39:16 Impact of large language models on the threat environment 
41:01 How to get in contact with the Sequretek team
 
Resources:
Company website: https://sequretek.com/
Facebook: https://www.facebook.com/sequretek.sqt

In this episode, we dive into the fascinating world of compliance and security with special guest Rachael Greaves, co-founder of Castlepoint, a tech company revolutionizing the industry. Rachael shares her journey, starting from her early days at Hitachi Data Systems, where she discovered her passion for storage systems and eventually found her way into the field of audit. Rachael's frustration with the constant shortcomings in compliance and security practices led her to invent a groundbreaking approach utilizing artificial intelligence. Together with co-founder Gavin McKay, she transformed their consulting company into a product company driven by AI technology. They recognized the critical need for advanced technology solutions in meeting compliance obligations, both in government and private entities.
 
Rachael also discusses her experience with a large military project audit, which inspired her to create Castlepoint. Feeling unsatisfied with the outcome, she embarked on a mission to help organizations succeed by offering a comprehensive approach to security and audit services. Castlepoint provides a unique lens, combining policy expertise with technical proficiency to protect assets and ensure compliance with security regulations. Audits, reviews, and risk assessments are just a few of the services they offer to help companies stay secure and compliant.
 
Furthermore, Rachael sheds light on the challenges organizations face in managing data and systems effectively. With the ever-growing volume and speed of data generation, and the multitude of systems in use, finding a solution that balances secure data management without compromising user, system, and network performance is a daunting task. Rachael emphasizes the need for innovative solutions that alleviate the burden on under-resourced governance teams.
 
If your company is looking to scale its AI initiatives, head over to Tesoro AI (www.tesoroai.com). We are experts in AI strategy, staff augmentation, and AI product development. 
 
Founder Bio: 
Rachael Greaves is a records and information management thought leader and designed the Castlepoint command and control product. Rachael has consulted on large-scale records, security, and audit projects in government and regulated industries with complex integrated environments, and developed Castlepoint in response to the tension seen in organizations between compliance, usability, sustainability, and cost. Rachael is a Certified Information Professional (CIP), Certified Information Systems Auditor (CISA), Certified Information Security Manager (CISM), and Certified Data Privacy Systems Engineer (CDPSE), and is certified in project, change, and records management. With a cultural anthropology and linguistics background, Rachael brings ethical, global, and sustainable practices to the sector. Her innovative technology concept has transformed the compliance and risk management outcomes of multiple organizations, by automating the application of complex and multi-layered regulatory obligations to their data holdings. Rachael’s mission is to improve outcomes for citizens and stakeholders by helping governments and organizations to provide better, more accountable services.
 
Time Stamps: 
02:14 Rachael’s background and journey on AI 
05:16 Audit compliance and AI solutions for the government and corporate entities 
09:50 Castlepoint product company: exploring solutions to data management
13:56 AI-powered records management
20:27 Difference between automation and supervised machine learning
23:41 Exploring AI solutions for records retention schedules
27:53 Benefits of rules as code modeling for regulatory compliance
29:15 Analysis of Castlepoint AI for state government entity inquiry
32:41 AI-powered abuse detection
34:17 Benefits of using Castlepoint for compliance and data destruction
38:10 Benefits of Castlepoint for data management and AI model compliance
40:10 Risks associated with AI: r

In this episode, we delve into the fascinating world of AI-driven drug discovery and its potential to revolutionize the field of structural biology. Our guest, Raphael Townshend, the founder of Atomic AI, shares his journey from engineering to AI and his profound interest in the structural biology space. Raphael discusses his background in engineering and how his focus on AI, particularly computer vision, led him to pursue a Ph.D. in AI with a keen interest in structural biology. He explains how he discovered the relatively unexplored area of structural biology and recognized its potential for AI algorithms to make a significant impact.
The conversation takes a deeper dive into the potential impacts of AI on drug discovery, with a particular focus on its application in finding cures for diseases with no known remedy, including Alzheimer's, Parkinson's, various cancers, and infectious diseases. Raphael explains how AI has already demonstrated remarkable success in folding molecules, an achievement that once required extensive time and resources. By leveraging AI algorithms, researchers can now significantly reduce the time and cost involved in the drug discovery process.
Discover how AI algorithms are reshaping the landscape of drug discovery and paving the way for more efficient and cost-effective treatments. Tune in to this episode to explore the future possibilities of AI in structural biology and its potential to transform healthcare and improve countless lives.
If your company is looking to scale its AI initiatives, head over to Tesoro AI (www.tesoroai.com). We are experts in AI strategy, staff augmentation, and AI product development.

Founder Bio:
Raphael Townshend is the Founder and Chief Executive Officer at Atomic AI, a biotechnology company using artificial intelligence to enable the next generation of RNA drug discovery. Prior to founding Atomic AI, Raphael studied for his Ph.D. at Stanford University, where he wrote his thesis on Geometric Learning of Biomolecular Structure and taught in Stanford’s machine learning and computational biology programs. He has been recognized in Forbes 30 Under 30, and his work has been featured on the cover of Science, recognized by the Best Paper award at NeurIPS, and published in other top venues such as Nature, Cell, and ICLR. During his Ph.D. program, Raphael also held positions at DeepMind and Google on their artificial intelligence and software engineering teams and founded the inaugural workshop on machine learning and structural biology.
Time Stamps:
 
02:53 Raphael’s background and professional journey in AI
05:36 What are structural biology and the rational design of molecules
08:02 Impact of AI on drug discovery and medical research
09:18 Molecule design for undruggable diseases with AI-guided drug discovery
13:39 Designing RNA molecules for disease treatment using ai algorithms
15:30 Collecting data for AI model training
17:44 Exploring data generation for AI-powered RNA analysis
18:56 Complementing biological and AI scientists for AI model training
20:44 Predicting 3-dimensional protein shapes using machine learning
22:58 Exploring the Pharmaceutical and biotech industry
25:53 Structuring deals for startups in the biotech industry
27:55 Building a biotech company: found raising journey
30:49 Techbio investing and business modeling
34:06 Benefits of partnering models in Biotech and AI product usability
37:53 Progress in RNA drug discovery and AI-powered research
39:04 How to get in contact with the Atomic AI team
 
Resources:
Company website: https://atomic.ai/
Twitter: https://twitter.com/AtomicAICo
LinkedIn: https://www.linkedin.com/company/atomic-ai-rna/